For a patient with an embolic stroke on MRI, is it appropriate to prescribe Xarelto (rivaroxaban) 15 mg twice daily?

Xarelto 15 mg BID is NOT the appropriate dose for embolic stroke

For a patient with embolic stroke on MRI, the correct rivaroxaban (Xarelto) dosing is 20 mg once daily (or 15 mg once daily if CrCl 15-50 mL/min), NOT 15 mg twice daily. The 15 mg BID regimen is exclusively used for the initial 3 weeks of acute venous thromboembolism treatment, not for stroke prevention 1, 2.

Critical Dosing Distinction

The confusion likely stems from rivaroxaban having different dosing regimens for different indications:

For Stroke Prevention in Atrial Fibrillation (the likely indication here):

• Standard dose: 20 mg once daily with the evening meal 3, 2
• Renal adjustment: 15 mg once daily (not BID) if CrCl 15-50 mL/min 4
• Contraindicated: CrCl <15 mL/min 3

For Acute VTE Treatment ONLY:

• Initial 3 weeks: 15 mg BID
• Maintenance: 20 mg once daily 1, 5, 6

Clinical Algorithm for Embolic Stroke

Step 1: Determine the stroke etiology

• If embolic stroke is due to atrial fibrillation (most common): Use rivaroxaban 20 mg once daily
• If embolic stroke of undetermined source (ESUS): Rivaroxaban showed no benefit over aspirin 7, 8

Step 2: Assess renal function

• CrCl >50 mL/min: 20 mg once daily
• CrCl 15-50 mL/min: 15 mg once daily (NOT twice daily)
• CrCl <15 mL/min or dialysis: Do not use rivaroxaban 2

Step 3: Timing of initiation after acute stroke

• Small-to-moderate stroke (NIHSS <9): Can initiate within 3-14 days 9
• Large stroke: Delay anticoagulation for 14 days to reduce hemorrhagic transformation risk 10
• Presence of petechial hemorrhagic transformation on MRI does not preclude early rivaroxaban use 9

Evidence Supporting Once-Daily Dosing

The ROCKET-AF trial established rivaroxaban 20 mg once daily as noninferior to warfarin for stroke prevention in AF, with similar major bleeding rates but fewer intracranial hemorrhages 3, 10. The once-daily regimen was specifically chosen based on pharmacokinetic modeling and phase II/III trials demonstrating adequate efficacy and improved compliance compared to twice-daily dosing 11.

Common Pitfall

The 15 mg BID dose has never been studied or approved for stroke prevention. Using this regimen would represent off-label dosing without evidence of efficacy or safety. The PIONEER AF-PCI trial did evaluate 15 mg once daily (with dose reduction to 10 mg in renal impairment) in AF patients undergoing PCI, but this was combined with antiplatelet therapy in a specific post-PCI context 12.

Key Contraindications to Verify

• Mechanical heart valve or moderate-severe mitral stenosis (use warfarin instead) 10
• Severe renal failure (CrCl <15 mL/min)
• Active pathological bleeding
• Concomitant use with strong CYP3A4 inducers like carbamazepine 13